BioNTech Results Presentation Deck
First Quarter 2020 Financial Results (unaudited) - Profit and Loss
●
●
●
●
9
Cash and cash equivalents of EUR 452m (USD 495m) as of March 31, 2020
Additional EUR 217m (USD 236m) due in 2Q 2020 from Pfizer and Fosun Pharma (equity investments and non-dilutive deal upfront payments, partially
received already)
Net cash used in operating activities and investments into property, plant and equipment on track with previous guidance of EUR 300m (USD 329m¹) for
base business plan (prior to impact of Neon Therapeutics acquisition and BNT162 program)
Majority of BioNTech development costs for BNT162 program in 2020 will be funded via Pfizer and Fosun Pharma cost sharing, equity investments and
upfront payments.
(in million)
Revenues resulting from collaboration and license agreements
Revenues from other sales transactions
Total revenues
Cost of sales
Gross profit
Research and development expenses
Sales and marketing expenses
General and administrative expenses
Other operating income less expenses
Finance income less expenses
Income taxes
Loss for the period
1 Rate German Central Bank as of March 31, 2020
Three months ended
March 31,
2019
€ 21.9
4.3
€ 26.2
2020
€ 21.2
6.5
€ 27.7
(5.9)
€ 21.8
(65.1)
(0.5)
(15.8)
0.3
5.9
€ (53.4)
(3.3)
€ 22.9
(57.2)
(0.5)
(9.3)
0.3
3.0
€ (40.8)
BIONTECHView entire presentation